View More Recent Stories
-
Cidara Therapeutics (CDTX) Files for 7.04M Share Offering by Selling Stockholders
-
Cidara Therapeutics (CDTX) Announces $105 Million Private Placement
-
Cidara Therapeutics (CDTX) Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
-
Cidara Therapeutics (CDTX) Announces Scientific Advisory Board with Infectious Disease Experts
-
Cidara Therapeutics (CDTX) Restructures Workforce to Focus on Planned Clinical Development of CD388
-
Cidara Therapeutics (CDTX) Halted, News Pending
-
Cidara Therapeutics (CDTX) Appoints Jim Beitel as Chief Business Officer
-
H.C. Wainwright Upgrades Cidara Therapeutics (CDTX) to Buy
-
Cidara Therapeutics (CDTX) Misses Q2 EPS by 2051c
-
Cidara Therapeutics (CDTX) Files for 16.8M share Offering by Selling Stockholders
